Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Neither MOTS-c nor KPV is FDA-approved as a drug product. The research described here is primarily preclinical or early-stage. Consult a licensed healthcare provider before considering any peptide-based treatment.
In the expanding universe of peptide science, two molecules are attracting sustained research attention for reasons that go beyond the gym culture that often surrounds peptide discussions: MOTS-c and KPV. Both are short peptides with origins in endogenous biology — meaning they are derived from or mimic molecules the human body already produces — and both are showing early signals of relevance to inflammation, metabolism, and longevity.
MOTS-c: A Peptide From Your Own Mitochondria
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S ribosomal RNA-c) is unusual in peptide biology for a specific reason: it is encoded not in nuclear DNA but in mitochondrial DNA. This makes it what researchers call a mitochondrial-derived peptide (MDP), a class of signaling molecules that has become one of the more active areas of geroscience in the last decade.
First characterized by researchers at the University of Southern California in 2015, MOTS-c has been studied primarily for its role in metabolic regulation and exercise response. Key findings from preclinical research include:
Metabolic and Exercise Effects
Animal studies have shown that MOTS-c administration enhances insulin sensitivity, reduces adiposity, and improves exercise capacity — even in older animals where these parameters typically decline. A 2023 study in aged mice showed that MOTS-c injection partially reversed age-related declines in muscle function and metabolic flexibility.
Longevity Signaling
MOTS-c levels decline with age in humans, and higher circulating MOTS-c has been associated with healthier aging phenotypes in observational studies. Researchers at the National Institute on Aging are currently investigating MOTS-c as part of a broader program on mitochondrial-derived peptides and longevity.
A 2025 review in Nature Reviews Endocrinology described MOTS-c as “one of the most promising endogenous peptides for understanding the molecular basis of exercise’s health benefits,” noting that exogenous administration mimics several effects of physical activity at the cellular level.
Where the Research Stands
No human clinical trials of MOTS-c have been published as of early 2026. The preclinical evidence is compelling but limited to animal models. MOTS-c is not classified by the FDA as a bulk drug substance eligible for 503A compounding (it is not on the Category 1, 2, or 3 list as of April 2026), which creates an uncertain legal status for any compounded preparations.
Researchers working on MOTS-c emphasize that moving from mouse models to human therapeutics requires careful dose-response characterization, safety studies, and ultimately clinical trials — a process that may take another 5–10 years before a regulated therapeutic is available.
KPV: An Anti-Inflammatory Tripeptide
KPV (Lys-Pro-Val) is a tripeptide — just three amino acids — derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH). It has been studied primarily for its anti-inflammatory properties, with a research focus on gastrointestinal conditions.
Gut Inflammation Research
The most developed body of evidence for KPV comes from inflammatory bowel disease (IBD) models. Multiple studies have demonstrated that KPV can reduce intestinal inflammation in colitis models by inhibiting the NF-κB signaling pathway, a key driver of inflammatory cascades in the gut.
A 2024 study in PLOS ONE showed that oral nanoparticle-encapsulated KPV significantly reduced colitis severity in mouse models, with the nanoparticle delivery system helping to protect the peptide from degradation in the GI tract. The researchers noted that KPV’s very short amino acid sequence makes it relatively stable compared to longer peptides and potentially amenable to oral delivery — an advantage most peptides lack.
Skin and Systemic Inflammation
Earlier research explored KPV’s anti-inflammatory effects in skin conditions, including contact dermatitis and psoriasis models. Topical KPV formulations showed efficacy in reducing inflammatory cytokine expression in animal models.
What Remains Unknown
KPV human trial data is absent as of 2026. The preclinical evidence in IBD models is promising enough that at least two academic medical centers have filed IND (Investigational New Drug) applications with the FDA to begin Phase 1 studies, but those trials have not yet begun enrollment.
Like MOTS-c, KPV is not on the FDA’s 503A bulk drug substance list, placing any compounded preparations in an unresolved legal gray area.
The Broader Context: Why These Peptides Matter
MOTS-c and KPV represent a growing category of research — peptides derived from or inspired by endogenous biology rather than designed de novo. This approach carries a theoretical safety advantage (the body already handles related molecules) and a scientific appeal (they may restore or amplify biological processes that decline with age or disease).
Neither peptide is ready for clinical use outside of a research context. But the trajectory of the research — particularly for MOTS-c in metabolic aging and KPV in GI inflammation — suggests these are names worth tracking.
Informed Peptide will continue to report on developments in MOTS-c and KPV research as clinical trial data becomes available.
Sources: Lee C et al., Cell Metabolism (2015); Reynolds PR et al., PLOS ONE (2024); Kim SJ et al., Nature Reviews Endocrinology (2025); NIA Intramural Research Program (ongoing). This article reflects published research as of April 2026 and should not be interpreted as clinical guidance.
Stay Informed on Peptide Research
Get the latest peptide research, regulatory updates, and clinical findings delivered to your inbox weekly. No spam — unsubscribe anytime.
No spam. Unsubscribe at any time. See our Privacy Policy.